Patents by Inventor Joerg Rademann

Joerg Rademann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer
    Patent number: 10683286
    Abstract: A furazan-3-carboxylic acid derivative or pharmaceutically acceptable salt thereof for treatment of acute myeloid leukemia.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 16, 2020
    Assignee: FREIE UNIVERSITAET BERLIN
    Inventors: Joerg Rademann, Ee Lin Wong, Christoph Arkona, Boo Geun Kim, Eric Nawrotzky
  • NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER
    Publication number: 20190382392
    Abstract: A furazan-3-carboxylic acid derivative or pharmaceutically acceptable salt thereof for treatment of acute myeloid leukemia.
    Type: Application
    Filed: October 5, 2017
    Publication date: December 19, 2019
    Inventors: Joerg Rademann, Ee Lin Wong, Christoph Arkona, Boo Geun Kim, Eric Nawrotzky
  • Shp-2 inhibitors and pharmaceutical compositions comprising them
    Patent number: 7868185
    Abstract: The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: January 11, 2011
    Assignees: Max-Delbruck-Centrum fur Molekulare Medizin, Forschungsverbund Berlin E, V.
    Inventors: Klaus Hellmuth, Walter Birchmeier, Joerg Rademann, Stefanie Grosskopf
  • Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases
    Publication number: 20080194563
    Abstract: The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).
    Type: Application
    Filed: June 1, 2006
    Publication date: August 14, 2008
    Inventors: Klaus Hellmuth, Walter Birchmeier, Joerg Rademann, Stefanie Grosskopf
  • Peg-based macromonomers, chemically inert polymers prepared therefrom and the use of these polymers for organic synthesis and enzyme reactions
    Patent number: 7064179
    Abstract: The present invention relates to macromonomers containing ethylene glycol repeat units, to chemically inert polymers prepared therefrom and to the use of such polymers in solid phase biochemical assays.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: June 20, 2006
    Assignee: Carlsberg A/S
    Inventors: Morten Meldal, Jens Buchardt, Joerg Rademann
  • Substituted ethane-1,2-diamines for the treatment of Alzheimer's disease
    Publication number: 20060025345
    Abstract: The invention relates to a compound of the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, A, B, and Y are defined as in the specification and claims and to its use for treating or preventing Alzheimer's disease and other similar diseases.
    Type: Application
    Filed: May 20, 2005
    Publication date: February 2, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Stefan Peters, Christian Eickmeier, Klaus Fuchs, Werner Stransky, Cornelia Dorner-Ciossek, Marcus Kostka, Sandra Handschuh, Margit Bauer, Herbert Nar, Klaus Bornemann, Klaus Klinder, Joerg Rademann, Steffen Weik